IRVINE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) — Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that the company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to the market open on Monday, December 24, 2018.
The Nasdaq Biotechnology Index (NBI) is designed to track the performance of a set of NASDAQ-listed securities that meet certain eligibility criteria and are classified as either biotechnology or pharmaceuticals, according to the Industry Classification Benchmark (ICB). These requirements include minimum market capitalization and average daily trading volume. The NBI is ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For more information about the Nasdaq Biotechnology Index visit https://indexes.nasdaqomx.com.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate Jeuveau, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Investors:
Ashwin Agarwal, Evolus
Tel: +1-949-284-4559
Email: IR@Evolus.com
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com
General Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com
Trade Media:
Dani Shaffer, Alison Brod Marketing + Communications
Tel: +1-212-230-1800
Email: evolus@alisonbrodmc.com